Payment overview · 2025
General Payments
$745.90
30 reported records · 11 companies
Healthcare provider profile · identity verified
Mona S Shah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN PEDRO, CA · NPI 1609087543
Verified facts
What the public records show
CMS Open Payments records show Mona S Shah, MD received $745.90 in general payments during 2025 across 30 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $150.00 | 20.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.60 | 18.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.26 | 13.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.04 | 10.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.43 | 9.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.02 | 7.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.66 | 5.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.85 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.10 | 4.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.93 | 3.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.01 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $595.90 | 29 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $138.60 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $128.59 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.43 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.02 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.79 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.66 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.66 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 69 |
| Famotidine | Famotidine | 263 | 62 |
| Eliquis | Apixaban | 234 | 24 |
| Losartan Potassium | Losartan Potassium | 234 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 54 |
| Gabapentin | Gabapentin | 223 | 59 |
| Celecoxib | Celecoxib | 201 | 55 |
| Metformin Hcl | Metformin Hcl | 194 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 39 |
| Furosemide | Furosemide | 146 | 43 |
| Lisinopril | Lisinopril | 142 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 33 |
| Simvastatin | Simvastatin | 119 | 45 |
| Donepezil Hcl | Donepezil Hcl | 112 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 19 |
| Mirtazapine | Mirtazapine | 98 | 19 |
| Trazodone Hcl | Trazodone Hcl | 96 | 29 |
| Januvia | Sitagliptin Phosphate | 92 | 18 |
| Tramadol Hcl | Tramadol Hcl | 90 | 30 |
| Omeprazole | Omeprazole | 76 | 23 |
| Ozempic | Semaglutide | 68 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 17 |
| Carvedilol | Carvedilol | 57 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 17 |
| Lactulose | Lactulose | 50 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 27 |
| Ibuprofen | Ibuprofen | 46 | 28 |
| Montelukast Sodium | Montelukast Sodium | 45 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 16 |
| Megestrol Acetate | Megestrol Acetate | 42 | 13 |
| Prednisone | Prednisone | 40 | 18 |
| Bethanechol Chloride | Bethanechol Chloride | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 15 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Jardiance | Empagliflozin | 35 | 13 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Invokana | Canagliflozin | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | 11 |
| Meloxicam | Meloxicam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 14 |
| Glipizide | Glipizide | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Nystatin | Nystatin | 22 | 12 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 11 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Colchicine | Colchicine | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ztlido | Lidocaine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.90 · 30 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, ACCRUFER, Auvelity, COMIRNATY, FREESTYLE LIBRE 3, JARDIANCE, MAVYRET, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, ZTLido | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error